Core Insights - The National Investment Group has invested in 118 projects in the biomanufacturing sector, amounting to 22.5 billion yuan, which has driven investments exceeding 100 billion yuan [1][4] - The "14th Five-Year Plan" emphasizes the need for forward-looking layouts in future industries, positioning biomanufacturing as a new economic growth point [1] Investment and Development - The National Investment Group's Biomanufacturing Innovation Research Institute signed a share transfer agreement with Dongsheng Biotechnology, initiating a new protein industrialization project [2] - This collaboration aims to establish a complete chain of "technology research and development + industrial implementation" in the new protein sector, enhancing the role of state-owned enterprises in technology leadership and industrial promotion [2][5] - The new protein industry, based on synthetic biology technology, aims to reform traditional protein acquisition methods through industrial microbial fermentation [2] Market Potential - The biomanufacturing industry is expected to grow from 16 trillion yuan in 2025 to 30 trillion yuan by 2030, indicating a significant market expansion [2] - New protein concepts have emerged in the context of food security and sustainable development, aiming to reduce reliance on traditional livestock farming [2] Strategic Initiatives - The State-owned Assets Supervision and Administration Commission launched initiatives focusing on 15 key industries, including biomanufacturing, to accelerate the development of emerging industries [4] - The National Investment Group is the leading entity in cultivating the biomanufacturing industry, with a registered capital of 6 billion yuan for its innovation research institute [4] - The investment strategy combines direct investment and fund management to accelerate the growth of the biomanufacturing sector [4] Industry Leadership - The National Investment Group has invested in 98 projects in the biopharmaceutical sector, totaling 18.4 billion yuan, which has attracted over 108.6 billion yuan in social capital [4] - Companies like Innovent Biologics and Kelun-Biotech, backed by the National Investment Group, have become industry leaders [4] - Dongsheng Biotechnology is recognized as a leading global enterprise in glutaminase transaminase, with a 60% market share in China and products exported to 43 countries [4]